Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cellular Biomedicine Group, Inc. (NASDAQ: CBMG).

Full DD Report for CBMG

You must become a subscriber to view this report.


Recent News from (NASDAQ: CBMG)

Cellular Biomedicine misses by $0.21, beats on revenue
Cellular Biomedicine (NASDAQ: CBMG ): Q3 GAAP EPS of -$0.72 misses by $0.21 . More news on: Cellular Biomedicine Group, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 06 2018 07:22
Cellular Biomedicine Group Reports Third Quarter Financial Results and Recent Business Highlights
Debuted its next 12-18 months’ immuno-oncology clinical development programs for both hematologic malignancies and solid tumors to key opinion leaders, investment and industry executives Licensed patents from the National Cancer Institute (“NCI”) to develop the next g...
Source: GlobeNewswire
Date: November, 06 2018 06:56
Cellular Biomedicine Group to Provide Company Cancer Immunotherapy Pipeline Update and Facility Tour for Attendees of the Advanced Cell Therapy Summit in Shanghai
SHANGHAI, China and CUPERTINO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc . (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem c...
Source: GlobeNewswire
Date: October, 25 2018 08:56
Week In Review: Shanghai Henlius To File For Hong Kong IPO At Valuation Of Over $1 Billion
Deals and Financings Shanghai Fosun Pharma (HK: 02196: SHA: 600196) announced it will seek a Hong Kong IPO for Shanghai Henlius Biotech, its monoclonal antibody JV subsidiary. At the same time, the company will withdraw its application for a listing on China's Third Board, the National Equit...
Source: SeekingAlpha
Date: October, 07 2018 07:20
Cellular Biomedicine Group Obtained NCI Patent License for Next Generation Neoantigen-Reactive Tumor Infiltrating Lymphocyte (TIL) Technology to Treat  Solid Tumors
SHANGHAI, China and CUPERTINO, Calif., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc . (NASDAQ: CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of immunotherapies for cancer and stem cell...
Source: GlobeNewswire
Date: October, 03 2018 07:30
Week In Review: Agilent Pays $250 Million To Acquire ACEA And Its Cell Therapy Analyzer
Deals And Financings ACEA Biosciences, a San Diego company with R&D and manufacturing facilities in Hangzhou, will be acquired by Agilent (NYSE: A) for $250 million in cash (see story ). ACEA has developed the xCELLigence® cell therapy analysis device intended for academic and biop...
Source: SeekingAlpha
Date: October, 01 2018 05:26
Cellular Biomedicine inks deal with Novartis for CAR-T cell therapy for patients in China
Cellular Biomedicine Group (NASDAQ: CBMG ) has entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah (tisagenlecleucel) in China. Novartis will be the exclusive holder of the marketing license. More news...
Source: SeekingAlpha
Date: September, 27 2018 08:52
Cellular Biomedicine Group Enters Into Strategic Licensing and Collaboration Agreement with a Global Leader in CAR-T Cell Therapy for Patients in China
Collaboration with Novartis includes $40 million equity investment in CBMG for 1,458,257 shares at $27.43 /share CBMG to license select proprietary technology to Novartis for global use CBMG to manufacture and supply Kymriah® (tisagenlecleucel) in China SHANGHAI and ...
Source: PR Newswire
Date: September, 27 2018 07:30

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-1419.4719.3019.7518.7777,640
2018-12-1320.1319.7220.19919.396841,164
2018-12-1220.2820.1020.404319.31342,069
2018-12-1118.6720.2820.3518.051105,512
2018-12-1018.7918.5520.2017.4448,866

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-148,26527,30030.2747Cover
2018-12-137,92415,48851.1622Short
2018-12-127,19713,68252.6020Short
2018-12-1120,63945,57345.2878Short
2018-12-107,5099,86576.1176Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CBMG.


About Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)

Logo for Cellular Biomedicine Group, Inc. (NASDAQ: CBMG)

Cellular Biomedicine Group, Inc. CBMG is a biomedicine firm engaged in the development of new treatments for cancerous and degenerative diseases utilizing proprietary cell technologies, which include, without limitation, i haMPC human adipose derived mesenchymal progenitor cells for treatment of joint disease, ii huMPC human umbilical cord derived mesenchymal progenitor cells , iii TC DC tumor cell specific dendritic cells for treatment of a broad range of cancers and iv MNP human embryo derived motor neuron precursor cells and NP human embryo derived neuronal precursor cells for treatment of central nervous system diseases.

 

 

 

Current Management

  • Wei William Cao / CEO, President
  • Biz Tony Liu / CFO, Secretary
  • Andrew Chan / SVP, Corp. Dev.
  • Sarah Kelly / Director, Comm., Director, Inv. Rel.
  • Jeffrey Auerbach /
  • Terry A. Belmont /
  • David Bolocan /
  • Wei William Cao /
  • Jianping Dai /
  • Gerardus A. Hoogland /
  • Nadir Patel /
  • Keith Wong /

Current Share Structure

  • Market Cap: $321,374,995 - 05/11/2018
  • Issue and Outstanding: 17,003,968 - 02/11/2018

 


Recent Filings from (NASDAQ: CBMG)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 30 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 19 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: April, 11 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 09 2018
Pre-effective amendment to an S-3 filing
Filing Type: S-3/AFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 16 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 12 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 12 2018

 

 


Daily Technical Chart for (NASDAQ: CBMG)

Daily Technical Chart for (NASDAQ: CBMG)


Stay tuned for daily updates and more on (NASDAQ: CBMG)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CBMG)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CBMG is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of CBMG and does not buy, sell, or trade any shares of CBMG. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/